Servier gets an option to develop and sell GeNeuro’s multiple sclerosis candidate
Servier SA took an option to join in on the development of GeNeuro SA’s GNbAC1, a Phase II monoclonal antibody aimed at a causal factor of multiple sclerosis.
- Large Molecule
- Includes Equity
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.